Pacira生物科學 PCRX 深 滬
等待開盤 05-20 09:30:00 美东时间
22.31
-0.130
-0.58%
華盛通- 最 高22.87
- 今 開22.54
- 成交量 44.10万股
- 最 低 22.17
- 昨 收 22.44
- 總市值 8.78亿
- 52周最高 27.64
- 市盈率 靜 142.83
- 換手率 1.12%
- 52周最低 18.80
- 委 比 -26.36%
- 總股本 3934.79万
- 歷史最高 121.95
- 量 比 0.99
- 振 幅 3.12%
- 歷史最低 6.51
- 每 手 1
- 風險率 1.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Pacira BioSciences urges stockholders to vote "FOR" its three highly qualified director nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—on the BLUE proxy card for the 2026 Annual Meeting. The company highlights the nominees' extensive experience in healthcare, biopharmaceuticals, and leadership, aligning with Pacira's 5x30 strategy for sustainable growth. In contrast, Pacira criticizes DOMA's nominees for lacking industry exp...
05-12 20:01
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences, Inc. granted inducement awards to ten new employees on May 4, 2026, under its 2014 Inducement Plan, approved by the People & Compensation Committee without stockholder approval. Three employees received stock options for 36,800 shares, and ten received restricted stock units for 27,700 shares. The stock options have a 10-year term, a four-year vesting schedule, and an exercise price of $24.69 per share. The restricted stock un...
05-08 12:00
美股大行评级 | 苹果获多家机构上调目标价，最高至335美元；闪迪获华尔街大行看多至2000美元
今日重点评级关注：Benchmark：维持史密斯微软件"买入"评级，目标价从2美元升至2.5美元；Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元
05-04 16:04
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $32.
05-01 19:22
Pacira BioSciences Q1 2026 Earnings Call Transcript
On Thursday, Pacira BioSciences (NASDAQ:PCRX) discussed first-quarter financial...
05-01 05:27
Pacira BioSciences Affirms FY2026 Sales Guidance of $745.000M-$770.000M vs $759.317M Est
Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in millions)2026 Financial GuidanceAmountEXPAREL net product sales$600 to $620Total revenues$745 to $770Non-GAAP gross
05-01 04:02
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Pacira CFO Shawn Cross disposes 12,059 common shares for $303,299.99
Pacira CFO Shawn Cross disposes 12,059 common shares for $303,299.99 Pacira BioSciences CFO Shawn Cross sold 12,059 shares in transactions dated April 20-22. Sales were priced at USD 25.14 per share on April 20, USD 25.01 per share on April 21-22. Cross exercised stock options for 12,059 shares at U
04-23 08:03
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 63.4% to $9.59 dur...
04-17 05:05
Pacira BioSciences Presents Data From Three Studies Supporting Economic Value Of EXPAREL In Total Hip Arthroplasty And Total Knee Arthroplasty Procedures
Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented data from three real-world studies
04-13 20:08
